| Indication | ‒ Healing of all grades of erosive esophagitis (EE) ‒ Maintaining healing of EE ‒ Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) |
| Status | ‒ The commercialization partner, Par, received final approval in April 2017. ‒ US Launched in November 2022 by Par Pharmaceutical. |
| Product Advantages | ‒ Settled with the brand company. ‒ Final approval for 30mg and 60mg. |
| Market Size | Sales are conducted in the United States through business partners, with 2025 revenue of approximately 22.48 million. |
?
R&D
Dexlansoprazole DR Capsule
